Orchid Pharma earnings calls.

Orchid Pharma reported 15% YoY revenue growthCurrent 15% vs previous available quarter 0%. to ₹304Current reported value: 304. No comparable prior figure is available in the source record. crore in Q1 FY27, with EBITDA turning positive at ₹25Current 25 crore vs previous available quarter 42.3 crore. crore versus a ₹10 crore loss in Q1 FY26. Gross margin expanded 300bps YoY to 33%Current 300bps YoY to 33%. Reported change: +50pp QoQ (Q1)., driven by improved product mix and cost discipline. The merged entity (Orchid + Dhanuka Laboratories) saw FY26 revenue of ₹1,233 crore, down from ₹1,398 crore in FY25, reflecting the challenging Cephalosporin API environment. Management acknowledged overcapacity and pricing pressure persist in non-regulated markets, with regulated market demand cyclical—typically stronger in H2. Near-term priorities include protecting core volumes, improving margins through mix, and executing capital projects. The 7 ACA commissioning targets March 2027Current reported value: 7 ACA commissioning targets March 2027. No comparable prior figure is available in the source record., with 80-100% utilization ramp planned by end of first year. Integration synergies expected to emerge from FY28. Key risks include Chinese competitor pricing behavior post-7 ACA entry, regulatory approval timelines for Se Pro and Xif, and continued margin stress on Cefixime. Management counseled against assuming linear recovery, positioning this as a recovery quarter within an industry still navigating cyclical troughs.